Navigation Links
Cedars-Sinai Pathology and Laboratory Medicine chair recognized with 2 of the field's top honors
Date:9/28/2010

LOS ANGELES (SEPTEMBER 27, 2010) The College of American Pathologists has honored Mahul B. Amin, M.D., FCAP, chairman of the Department of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, with two awards for outstanding leadership and contributions in the field of pathology.

Amin was presented with both the College of Pathologists Distinguished Service Award and the College of Pathologists Foundation's Lansky Award at a ceremony in Chicago at the organization's annual scientific meeting. It is rare in the history of the College that a pathologist has been honored with both awards in the same year.

One of the nation's recognized authorities in prostate cancer pathology and oncologic pathology, Amin has written more than 244 articles in peer-reviewed journals, and has co-authored seven books, including two Armed Forces Institute of Pathology manuals.

The Lansky Award, in honor of Herbert Lansky, M.D., is presented to a board certified pathologist who has demonstrated leadership consistent with the goals of the CAP Foundation of promoting science and education in the field of pathology resulting in innovative improvements to patient care, identifying critical issues that affect the field and the public, and educating colleagues in the field and the public about pathology research.

"Dr. Mahul Amin's contributions to the field of pathology are truly remarkable, and span the entire spectrum of the field from research, to clinical practice, to key roles in standards and guideline development," said CAP Foundation President-Elect Jennifer L. Hunt, M.D., FCAP. "Dr. Amin embodies the mission of the Foundation, providing the best in patient-centered diagnostic service. We are so pleased to honor Dr. Amin with the Lansky Award, as a testament to his dedication to pathology and to patients."

The CAP Distinguished Service Award recognizes outstanding contributions to the practice of pathology and to the organization. Dr. Amin was honored with the award for his collaborative work in developing the CAP Cancer Protocols. The updated CAP Cancer Protocols, released late last year, serve to ensure standardization of pathology reporting throughout the United States for better patient care, and allow data to be more easily communicated and compared, which supports research efforts. The role of the pathologist in diagnosing cancer continues to expand as personalized medicine advances. The Cancer Protocols will be important tools to help pathologists worldwide rise to this challenge. Thanks to Amin's efforts, the cancer protocols are used widely throughout the world, including in Australia, Canada, and Asia.

"It is with great pleasure that we recognize Dr. Mahul Amin for his outstanding contributions to both the practice of pathology and to the College of American Pathologists," said CAP President Stephen N. Bauer, M.D., FCAP.


'/>"/>

Contact: Nicole White
nicole.white@cshs.org
310-423-5215
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Adults demonstrate modified immune response after receiving massage, Cedars-Sinai researchers show
2. Bigge Building Cedars-Sinai New West Tower
3. Cedars-Sinai heart transplantation tip sheet
4. Cedars-Sinai Medical Center Names Beverly Hills Plastic Surgeon Dr. Andrew Cohen as Chief of the Center for Plastic and Reconstructive Surgery
5. Cedars-Sinai study examines regional use of minimally invasive repair of aneurysms
6. Cedars-Sinai Heart Institute physicians present findings at ACC scientific meeting
7. Research team led by Cedars-Sinai identifies genes linked to ulcerative colitis
8. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
9. MUHC/McGill Ocular Pathology Laboratory celebrates a decade of progress
10. CAP Leaders, Policymakers Convene on the Future of Pathology
11. The Association for Molecular Pathology celebrates ruling in DNA patent case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: